Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes: Systematic Review and Meta-Analysis

Joseph Knapik, Rodney R Pope, Sally Hoedebecke, Ben Schram, Rob Marc Orr

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Osteoarthritis (OA) is a disorder involving the deterioration of
articular cartilage and underlying bone and is associated with
symptoms of pain and disability. In military personnel, the incidence
of OA has increased between 2000 and 2012 and was
the first or second leading cause of medical separations in this
period. It has been suggested that consumption of chondroitin
sulfate (CS) may reduce the pain and joint deterioration
associated with OA. This article reports on a systematic review
and meta-analysis of the effectiveness of CS on reducing
OA-related
pain and joint deterioration. PubMed and Ovid
Embase databases and other sources were searched to find
randomized, double-blind, placebo-controlled trials on the
effects of orally consumed CS on pain and/or joint structure.
The outcome measure was the standardized mean difference
(SMD) which was the improvement in the placebo groups minus
the improvement in the CS groups divided by the pooled
standard deviation. There were 18 trials meeting the review
criteria for pain with SMD –0.41, 95% confidence interval
(95% CI) –0.57 to –0.25 (negative SMD favors CS). Six studies
met the review criteria for joint space narrowing with SMD
–0.30, 95% CI –0.61 to +0.00. Two studies meet the review
criteria for cartilage volume with SMD –0.11, 95% CI –0.48
to +0.26. Larger dosages (1200mg/d) had greater pain reduction
efficacy than lower dosages (≤1000mg/d). These data suggest
that CS has small to moderate effectiveness in reducing
OA-related pain but minimal effects on joint space narrowing
and no effect on cartilage volume. It is important that clinicians
recommend pharmaceutical-grade CS to their patients
due to the variability in the amount of CS in dietary supplements
purporting to contain CS.
LanguageEnglish
Pages113-124
Number of pages12
JournalJournal of special operations medicine : a peer reviewed journal for SOF medical professionals
Volume19
Issue number1
Publication statusPublished - 19 Mar 2019

Fingerprint

Chondroitin Sulfates
Arthralgia
Osteoarthritis
Meta-Analysis
Cartilage
Pain
Joints
Confidence Intervals
Placebos
Military Personnel
PubMed
Outcome Assessment (Health Care)
Databases
Bone and Bones
Pharmaceutical Preparations

Cite this

@article{45c18318f10b4420a8cf900f96e9c740,
title = "Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes: Systematic Review and Meta-Analysis",
abstract = "Osteoarthritis (OA) is a disorder involving the deterioration ofarticular cartilage and underlying bone and is associated withsymptoms of pain and disability. In military personnel, the incidenceof OA has increased between 2000 and 2012 and wasthe first or second leading cause of medical separations in thisperiod. It has been suggested that consumption of chondroitinsulfate (CS) may reduce the pain and joint deteriorationassociated with OA. This article reports on a systematic reviewand meta-analysis of the effectiveness of CS on reducingOA-relatedpain and joint deterioration. PubMed and OvidEmbase databases and other sources were searched to findrandomized, double-blind, placebo-controlled trials on theeffects of orally consumed CS on pain and/or joint structure.The outcome measure was the standardized mean difference(SMD) which was the improvement in the placebo groups minusthe improvement in the CS groups divided by the pooledstandard deviation. There were 18 trials meeting the reviewcriteria for pain with SMD –0.41, 95{\%} confidence interval(95{\%} CI) –0.57 to –0.25 (negative SMD favors CS). Six studiesmet the review criteria for joint space narrowing with SMD–0.30, 95{\%} CI –0.61 to +0.00. Two studies meet the reviewcriteria for cartilage volume with SMD –0.11, 95{\%} CI –0.48to +0.26. Larger dosages (1200mg/d) had greater pain reductionefficacy than lower dosages (≤1000mg/d). These data suggestthat CS has small to moderate effectiveness in reducingOA-related pain but minimal effects on joint space narrowingand no effect on cartilage volume. It is important that cliniciansrecommend pharmaceutical-grade CS to their patientsdue to the variability in the amount of CS in dietary supplementspurporting to contain CS.",
author = "Joseph Knapik and Pope, {Rodney R} and Sally Hoedebecke and Ben Schram and Orr, {Rob Marc}",
year = "2019",
month = "3",
day = "19",
language = "English",
volume = "19",
pages = "113--124",
journal = "Journal of special operations medicine : a peer reviewed journal for SOF medical professionals",
issn = "1553-9768",
publisher = "U.S. Special Operations Command",
number = "1",

}

Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes : Systematic Review and Meta-Analysis. / Knapik, Joseph; Pope, Rodney R; Hoedebecke, Sally; Schram, Ben; Orr, Rob Marc.

In: Journal of special operations medicine : a peer reviewed journal for SOF medical professionals, Vol. 19, No. 1, 19.03.2019, p. 113-124.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effects of Oral Chondroitin Sulfate on Osteoarthritis-Related Pain and Joint Structural Changes

T2 - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals

AU - Knapik, Joseph

AU - Pope, Rodney R

AU - Hoedebecke, Sally

AU - Schram, Ben

AU - Orr, Rob Marc

PY - 2019/3/19

Y1 - 2019/3/19

N2 - Osteoarthritis (OA) is a disorder involving the deterioration ofarticular cartilage and underlying bone and is associated withsymptoms of pain and disability. In military personnel, the incidenceof OA has increased between 2000 and 2012 and wasthe first or second leading cause of medical separations in thisperiod. It has been suggested that consumption of chondroitinsulfate (CS) may reduce the pain and joint deteriorationassociated with OA. This article reports on a systematic reviewand meta-analysis of the effectiveness of CS on reducingOA-relatedpain and joint deterioration. PubMed and OvidEmbase databases and other sources were searched to findrandomized, double-blind, placebo-controlled trials on theeffects of orally consumed CS on pain and/or joint structure.The outcome measure was the standardized mean difference(SMD) which was the improvement in the placebo groups minusthe improvement in the CS groups divided by the pooledstandard deviation. There were 18 trials meeting the reviewcriteria for pain with SMD –0.41, 95% confidence interval(95% CI) –0.57 to –0.25 (negative SMD favors CS). Six studiesmet the review criteria for joint space narrowing with SMD–0.30, 95% CI –0.61 to +0.00. Two studies meet the reviewcriteria for cartilage volume with SMD –0.11, 95% CI –0.48to +0.26. Larger dosages (1200mg/d) had greater pain reductionefficacy than lower dosages (≤1000mg/d). These data suggestthat CS has small to moderate effectiveness in reducingOA-related pain but minimal effects on joint space narrowingand no effect on cartilage volume. It is important that cliniciansrecommend pharmaceutical-grade CS to their patientsdue to the variability in the amount of CS in dietary supplementspurporting to contain CS.

AB - Osteoarthritis (OA) is a disorder involving the deterioration ofarticular cartilage and underlying bone and is associated withsymptoms of pain and disability. In military personnel, the incidenceof OA has increased between 2000 and 2012 and wasthe first or second leading cause of medical separations in thisperiod. It has been suggested that consumption of chondroitinsulfate (CS) may reduce the pain and joint deteriorationassociated with OA. This article reports on a systematic reviewand meta-analysis of the effectiveness of CS on reducingOA-relatedpain and joint deterioration. PubMed and OvidEmbase databases and other sources were searched to findrandomized, double-blind, placebo-controlled trials on theeffects of orally consumed CS on pain and/or joint structure.The outcome measure was the standardized mean difference(SMD) which was the improvement in the placebo groups minusthe improvement in the CS groups divided by the pooledstandard deviation. There were 18 trials meeting the reviewcriteria for pain with SMD –0.41, 95% confidence interval(95% CI) –0.57 to –0.25 (negative SMD favors CS). Six studiesmet the review criteria for joint space narrowing with SMD–0.30, 95% CI –0.61 to +0.00. Two studies meet the reviewcriteria for cartilage volume with SMD –0.11, 95% CI –0.48to +0.26. Larger dosages (1200mg/d) had greater pain reductionefficacy than lower dosages (≤1000mg/d). These data suggestthat CS has small to moderate effectiveness in reducingOA-related pain but minimal effects on joint space narrowingand no effect on cartilage volume. It is important that cliniciansrecommend pharmaceutical-grade CS to their patientsdue to the variability in the amount of CS in dietary supplementspurporting to contain CS.

UR - http://www.scopus.com/inward/record.url?scp=85062889080&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 113

EP - 124

JO - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals

JF - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals

SN - 1553-9768

IS - 1

ER -